Skip to main content

Vaginal Moisturizers & Lubricants

Vaginal moisturizers and lubricants are nonhormonal options for genitourinary syndrome of menopause (GSM) and vulvovaginal dryness. They sit alongside vaginal estrogen, vaginal DHEA, and ospemifene among the GSM treatment options. They are nonhormonal options for women who prefer to avoid hormones and should be considered first-line for survivors of estrogen-dependent breast cancer.[3]

Moisturizers Versus Lubricants​

The two product classes are frequently conflated but serve distinct roles.[1][2]

Vaginal moisturizerVaginal lubricant
PurposeTrap moisture, restore mucosal hydration, longer-term symptom controlReduce friction and dyspareunia at intercourse
SiteIntravaginal; some formulations are also used on the vulva[6]Vaginal or vulvar application according to product directions[9]
ScheduleRegular use, most often 2–3 times per week (NAMS)[21]; product-specific regimens differAs-needed, immediately before intercourse
Effect on tissueMay improve dryness; pH and elasticity changes were reported for one polycarbophil moisturizer in a small 12-week study; benefits for itching and irritation are not established[4][22]Transient lubrication only

Small prospective studies of regular moisturizer use report improvement in vaginal moisture, elasticity and pH; in a 12-week open-label comparison (15 women per arm), a polycarbophil moisturizer and local estrogen cream both produced these changes.[22] Adequately powered placebo-controlled data remain sparse.[21]

Vaginal Moisturizers​

Formulations​

  • Hyaluronic acid–based and polycarbophil-based products are the most commonly used moisturizers.[2]
  • Polyacrylic acid and vitamin E / vitamin D vaginal suppositories are additional nonhormonal options with reported efficacy.[3] The ACOG 2021 consensus table lists example regimens from the trials: hyaluronic acid 5 mg daily for 2 weeks then 3–5 times per week; polycarbophil gel 2.5 g three times per week; polyacrylic acid 3 g daily; vitamin E 30–200 IU and vitamin D 1,000 IU suppositories. Evidence is from small trials, and ACOG found insufficient data to say one approach is superior.[3]
  • Regulatory classification is product-specific: many US personal lubricants and moisturizers are medical devices, including products cleared through FDA 510(k), rather than cosmetics or prescription hormone drugs.[15] Very little data exist on the safety of products containing flavors, warming agents, or preservatives such as parabens and propylene glycol; avoiding them is reasonable in patients with vulvar dermatoses or sensitive tissue. Moisturizers and lubricants can themselves irritate thin vulvovaginal tissue, and adding local vaginal hormone often improves tolerance.[14][21]

Evidence​

The evidence base is meaningful but of low certainty.

  • A 2024 systematic review (Annals of Internal Medicine, 46 RCTs, of which 6 included moisturizer arms (4 categorized as moisturizer trials and 2 as multiple-intervention trials)) found that vaginal moisturizers may improve dryness versus placebo, with low certainty of evidence. Most trials lasted 12 weeks or less. The same review rated vaginal estrogen, vaginal DHEA, and oral ospemifene as also improving GSM symptoms with similarly low certainty.[4]
  • The Mitchell 2018 RCT (JAMA Internal Medicine, n = 302) compared vaginal estradiol, a polycarbophil-based moisturizer, and dual placebo in women with moderate-to-severe vulvovaginal symptoms. At 12 weeks, all three groups had similar improvement in most-bothersome-symptom severity, and neither active treatment differed from dual placebo on that primary endpoint. Estradiol, but not moisturizer, improved vaginal pH and superficial-cell maturation versus placebo; more estradiol users also reported meaningful benefit, a secondary outcome.[5] This is interpreted either as a strong placebo effect from regular vaginal gel application, or as evidence that the moisturizing properties of the placebo gel were themselves therapeutic.
  • A 2023 systematic review of nonestrogen GSM therapies (Obstetrics & Gynecology) reinforced that moisturizers are an evidence-supported nonhormonal option without a clear best-in-class formulation.[8]

Moisturizers Versus Vaginal Estrogen​

The Garcia de Arriba 2022 RCT randomized 172 postmenopausal women; its 151-person per-protocol analysis found a hormone-free moisturizing cream non-inferior to 0.1% estriol cream on a four-symptom composite of dryness, itching, burning and noncoital pain at 43 days, while the daily-life impairment analysis was secondary.[6] In women whose dryness caused severe impairment of daily life, estriol cream was significantly superior (p = 0.0032).[6] The trial was open-label and manufacturer-sponsored. The 2026 EAU guideline, drawing on a systematic review, notes that vaginal estrogen outperforms lubricants and moisturizers on objective measures of vulvovaginal atrophy but not on subjective symptoms.[20] AUA/SUFU/AUGS 2025 recommends moisturizers and/or lubricants, alone or with other therapies, for vaginal dryness and dyspareunia (moderate recommendation, Grade C) and separately recommends offering low-dose vaginal estrogen (strong recommendation, Grade C). General GSM care does not require failure of moisturizers before low-dose vaginal estrogen. For urinary symptoms of GSM (frequency, urgency, leakage) and rUTI prevention, evidence has not established benefit from moisturizers or lubricants. AUA/SUFU/AUGS 2025 does not treat them as first-line for these symptoms and suggests pairing them with hormonal therapy.[14]

Vaginal Lubricants​

Lubricants are applied to the introitus before intercourse to reduce friction and dyspareunia, on an as-needed basis. ACOG endorses them as a nonhormonal option for friction-related dyspareunia.[1] NAMS 2020 lists nonhormonal lubricants with sexual activity as first-line therapy for less severe GSM (Level A).[21]

Lubricant Types​

TypeAdvantagesDisadvantagesCondom-compatible
Water-basedWidely available, easy cleanupDries out quickly causing friction; many are hyperosmolarCheck product and condom labeling
Silicone-basedLong-lasting, does not dry out, formulation-specific tolerabilitySome silicone-containing pessaries, vaginal rings, and toys may be incompatible[13]; more expensiveCheck product and device labeling
Oil-based (plant or petroleum)Inexpensive, long-lastingDegrades latex and polyisoprene condoms[16]; petroleum jelly was associated with more bacterial vaginosis and oils with more Candida colonization in one study[13][21]No (latex or polyisoprene)
Hyaluronic acid–basedPossible mucosal benefitLimited comparative dataVaries by product

Selection should account for condom compatibility, patient sensitivities and preference. ACOG notes that food-grade oils are inexpensive, water-based lubricants may dry quickly, and silicone lubricants do not dry and are compatible with latex condoms. Oil-based lubricants can weaken latex and polyisoprene condoms; check the material and product labeling of other synthetic condoms before using an oil-based lubricant.[2][16]

Osmolality and pH — An Underappreciated Selection Criterion​

Lubricant osmolality is linked to epithelial injury in laboratory models, but the clinical effects of specific osmolality or pH thresholds on vaginal health remain uncertain.[9][11][12] The WHO/UNFPA/FHI360 advisory distinguished an ideal osmolality ≤380 mOsm/kg from an interim procurement ceiling ≤1200 mOsm/kg; the latter is not an iso-osmolar definition.[16] Select pH and condom/fertility compatibility for the intended use rather than applying one range to every product. AUA/SUFU/AUGS 2025 cites the WHO 1,200 mOsm/kg ceiling and pH 5.0–7.0, while the 2012 WHO/UNFPA/FHI360 advisory recommends about pH 4.5 for primarily vaginal use and 5.5–7 for primarily rectal or unspecified use.[16][9][10][14] The 2026 WHO/UNFPA procurement specification for water-based lubricants gives pH 4.0–7.0 (allowable tolerance ±1.0) and osmolality <1200 mOsm/kg; these specifications are not proven clinical outcome thresholds.[26] Many commercial lubricants are markedly hyperosmolar.

  • Dezzutti 2012 evaluated 14 over-the-counter lubricants: hyperosmolar products (including KY Jelly and Astroglide) caused loss of epithelial viability and epithelial stripping in explant tissue. KY Jelly, Replens (a polycarbophil moisturizer) and a nonoxynol-9 spermicidal gel were also toxic to Lactobacillus in vitro. By contrast, nearly iso-osmolar products (Good Clean Love, PRÉ) and silicone-based lubricants showed no significant epithelial damage.[11] These are laboratory findings; clinical consequences have not been shown.
  • Wilkinson 2019 confirmed in 3-dimensional vaginal epithelial-cell models that hyperosmolar lubricants alter cell morphology and are selectively cytotoxic, inflammatory, and barrier-disrupting.[12]
  • Palacios 2023 open-label trial randomized 183 pre- and postmenopausal women to five water-based lubricants; 174 completed four weeks. Four products met the WHO interim ceiling (≤1200 mOsm/kg), and one had higher osmolality. FSFI improved within each arm. Gynecologic examinations assessed vaginal epithelial tolerance after one application in a 52-person subset, and vaginal microbiology was measured through four weeks; long-term mucosal safety remains untested.[9]

Irritant and compatibility assessment​

Review formulation and concentration, patient irritation history, and condom/fertility compatibility. Avoid products that cause symptoms; high osmolality, spermicides, fragrances, and warming additives can be problematic.[13][14]

Breast-Cancer Survivors​

ACOG's Clinical Consensus on urogenital symptoms in women with a history of estrogen-dependent breast cancer states that nonhormonal methods (moisturizers and lubricants) should be considered first-line treatment.[3] Low-dose vaginal estrogen may follow if these fail, after shared decision-making.[3] In a 2026 open-label RCT of 100 breast-cancer survivors after primary treatment, moisturizer used three times weekly improved 16-week vaginal health and vaginal/vulvar symptom scores more than lubricant used at intercourse; 88 completed follow-up. Different use schedules and lack of blinding limit any formulation-specific comparison.[23]

  • In a double-blind crossover RCT of breast-cancer survivors (n = 45 assessable), a polycarbophil-based moisturizer (Replens) and a placebo lubricating product both reduced dryness by about 60% (no difference). During the first 4 weeks, average dyspareunia scores decreased by 60% with the moisturizer versus 41% with placebo (P = .05).[17]
  • In a randomized double-blind crossover trial (n = 38 analyzed), silicone-based and water-based lubricants did not differ significantly on the primary measure of sexual discomfort (P = .06). A post hoc analysis favored silicone for penetration pain; among 31 women expressing a preference, 20 (65%) preferred silicone and 11 (35%) preferred water. Most women remained distressed with either product.[18]
  • Topical 4% aqueous lidocaine was tested for severe entry dyspareunia localized to a lidocaine-responsive vestibule, after exclusion of pelvic pain, pelvic-floor myalgia and vulvar dermatoses. Of 46 randomized breast-cancer survivors, 43 completed the 1-month blinded phase; among blinded-phase completers, 71% of saline users and 73% of lidocaine users attempted intercourse. In those who did, a 3-minute vestibular lidocaine compress plus silicone lubricant yielded median intercourse pain of 1.0 versus 5.3 with saline plus the same lubricant (0–10 scale, P = .007).[19]

Guideline Recommendations​

The American College of Obstetricians and Gynecologists (ACOG) states that nonestrogen water- or silicone-based lubricants and moisturizers may help with menopause-related vaginal symptoms, particularly for women who prefer to avoid hormonal therapy.[1] Its 2019 sexual dysfunction bulletin states that lubricants, topical anesthetics and moisturizers may help reduce or alleviate dyspareunia (Level C); they do not cure the underlying cause, and some products contain potential irritants such as parabens and propylene glycol.[2] An American Family Physician review identifies over-the-counter hormone-free vaginal products as reasonable first-line therapy for GSM, with lubricants used as needed for dyspareunia.[7] When lubricants or moisturizers are insufficient, escalation to vaginal estrogen, vaginal DHEA (prasterone), or oral ospemifene is guided by symptom severity and patient preference. For breast-cancer survivors, AUA/SUFU/AUGS 2025 states that clinicians may recommend low-dose vaginal estrogen within multidisciplinary shared decision-making (expert opinion), so hormonal escalation should involve the oncologist.[3][7][14]

Reconstructive Relevance​

Moisturizers and lubricants may improve dryness and comfort around pelvic care, but they have not established improved surgical healing, prolapse-repair durability, or prevention of pessary erosion. Resume vaginal products and intercourse after reconstruction according to the operating team's healing assessment. See priming evidence.

Practical Use​

  • Moisturizers: intravaginal application, most often 2–3 times per week, for ongoing symptom control; follow the product's own schedule.[1][7][21]
  • Lubricants: applied at the introitus immediately before intercourse, as needed.[1][2]
  • Product selection: choose by comfort, cost, sensitivities, intended use, and product-specific condom compatibility. Lower-osmolality options may be preferable when available; 1200 mOsm/kg is an upper procurement limit, not a physiological target.[14][16]
  • Treatment choice: moisturizers may be used alone or with other GSM therapies; moisturizer failure is not required before offering low-dose vaginal estrogen in general GSM care. Vaginal estrogen, vaginal DHEA (prasterone), and oral ospemifene are options according to symptoms and contraindications.[7][14] For patients with a breast-cancer history, use multidisciplinary shared decision-making: the Intrarosa label says prasterone has not been studied in this population, while the Osphena label says ospemifene should not be used with known, suspected, or prior breast cancer.[24][25]

References​

1. Committee on Practice Bulletins—Gynecology. "ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms." Obstet Gynecol. 2014;123(1):202–216. doi:10.1097/01.AOG.0000441353.20693.78

2. Committee on Practice Bulletins—Gynecology. "Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213." Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324

3. Committee on Clinical Consensus–Gynecology. "Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer: Clinical Consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601

4. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review." Ann Intern Med. 2024;177(10):1400–1414. doi:10.7326/ANNALS-24-00610

5. Mitchell CM, Reed SD, Diem S, et al. "Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial." JAMA Intern Med. 2018;178(5):681–690. doi:10.1001/jamainternmed.2018.0116

6. Garcia de Arriba S, Grüntkemeier L, Häuser M, et al. "Vaginal Hormone-Free Moisturising Cream Is Not Inferior to an Estriol Cream for Treating Symptoms of Vulvovaginal Atrophy: Prospective, Randomised Study." PLoS One. 2022;17(5):e0266633. doi:10.1371/journal.pone.0266633

7. Chang JG, Lewis MN, Wertz MC. "Managing Menopausal Symptoms: Common Questions and Answers." Am Fam Physician. 2023;108(1):28–39.

8. Casiano Evans EA, Hobson DTG, Aschkenazi SO, et al. "Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review." Obstet Gynecol. 2023;142(3):555–570. doi:10.1097/AOG.0000000000005288

9. Palacios S, Hood S, Abakah-Phillips T, Savania N, Krychman M. "A Randomized Trial on the Effectiveness and Safety of 5 Water-Based Personal Lubricants." J Sex Med. 2023;20(4):498–506. doi:10.1093/jsxmed/qdad005

10. Potter N, Panay N. "Vaginal Lubricants and Moisturizers: A Review Into Use, Efficacy, and Safety." Climacteric. 2021;24(1):19–24. doi:10.1080/13697137.2020.1820478

11. Dezzutti CS, Brown ER, Moncla B, et al. "Is Wetter Better? An Evaluation of Over-the-Counter Personal Lubricants for Safety and Anti-HIV-1 Activity." PLoS One. 2012;7(11):e48328. doi:10.1371/journal.pone.0048328

12. Wilkinson EM, Łaniewski P, Herbst-Kralovetz MM, Brotman RM. "Personal and Clinical Vaginal Lubricants: Impact on Local Vaginal Microenvironment and Implications for Epithelial Cell Host Response and Barrier Function." J Infect Dis. 2019;220(12):2009–2018. doi:10.1093/infdis/jiz412

13. Vanderschee R, Kostov S. "Approach to Lubricant Use for Sexual Activity." Can Fam Physician. 2025;71(7-8):e158–e166. doi:10.46747/cfp.710708e158

14. AUA/SUFU/AUGS. Genitourinary Syndrome of Menopause Guideline. 2025. Official guideline.

15. FDA. CVS Personal Lubricant & Moisturizer, 510(k)K062682. Device clearance summary.

16. WHO/UNFPA/FHI360. Use and procurement of additional lubricants with male and female condoms. 2012. Advisory note.

17. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. "Phase III Randomized Double-Blind Study to Evaluate the Efficacy of a Polycarbophil-Based Vaginal Moisturizer in Women With Breast Cancer." J Clin Oncol. 1997;15(3):969–973. doi:10.1200/JCO.1997.15.3.969

18. Hickey M, Marino JL, Braat S, Wong S. "A Randomized, Double-Blind, Crossover Trial Comparing a Silicone- Versus Water-Based Lubricant for Sexual Discomfort After Breast Cancer." Breast Cancer Res Treat. 2016;158(1):79–90. doi:10.1007/s10549-016-3865-1

19. Goetsch MF, Lim JY, Caughey AB. "A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial." J Clin Oncol. 2015;33(30):3394–3400. doi:10.1200/JCO.2014.60.7366

20. EAU Guidelines on Non-neurogenic Female Lower Urinary Tract Symptoms (LUTS). 2026. Section on oestrogen therapy.

21. The NAMS 2020 GSM Position Statement Editorial Panel. "The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society." Menopause. 2020;27(9):976–992. doi:10.1097/GME.0000000000001609

22. Nachtigall LE. "Comparative Study: Replens Versus Local Estrogen in Menopausal Women." Fertil Steril. 1994;61(1):178–180. doi:10.1016/S0015-0282(16)56474-7

23. Martin BC, Vitorino CN, Souza R, et al. "Effect of a non-hormonal vaginal moisturizer on vaginal and vulvar health in postmenopausal women with breast cancer: A randomized clinical trial." Maturitas. 2026;207:108880. doi:10.1016/j.maturitas.2026.108880

24. DailyMed. Intrarosa (prasterone) vaginal insert: US prescribing information. Revised January 2026. Current label.

25. DailyMed. Osphena (ospemifene) tablets: US prescribing information. Revised February 2025. Current label.

26. World Health Organization, United Nations Population Fund. World Health Organization/United Nations Population Fund specifications for personal lubricants. WHO Technical Report Series No. 1067, Annex 6. 2026:183–198. Official specification.